Original title: Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. Reference: Capodanno D et al. EuroIntervention. 2014 Jul 18. Epub ahead of print The GHOST-EU registry, that included 1189 patients from 10 European centers between 2011 and 2014, is now the largest registry...
Original title: Multislice Computed Tomography Angiography for Non-invasive Assessment of the 18-Months Performance of a Novel Radiolucent Bioresorbable Vascular Scaffolding Device (ABSORB Trial). Reference: Koen Nieman et al. J Am Coll Cardiol, article in press. Metal stents revolutionized coronary angioplasty procedures; however, they are permanent prosthetic devices that make re intervention difficult and prolongue thrombosis risk. This problem...
Original Title: One-year Clinical and Computed Tomography Angiographic Outcomes after Bioresorbable Vascular Scaffold Implantation during Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction. The Prague-19 Study. Reference: Widimsky P et al. Circ Cardiovasc Interv. 2015 Dec;8(12). Courtesy of Dr. Carlos Fava. Primary PCI is the most common course of treatment for ST elevation myocardial infarction (STEMI)...
Courtesy of Dr. Agustín Vecchia. The aim of this study was to compare the safety and efficacy of bioresorbable everolimus eluting scaffolds (BVS) vs. everolimus eluting stents (EES) in patients with ischemic heart disease. Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), was searched for scientific sessions, abstracts, and relevant websites for...
Original title: 1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds A Pooled Analysis of the ABSORB and the SPIRIT Trials. Reference: Muramatsu T et al. JACC CardiovascInterv. 2014 May;7(5):482-93. This study included ABSORB, ABSORB Extend and SPIRIT patients. A total of 136 diabetic patients and 415 non diabetic receiving everolimus-eluting bioresorbable scaffolds (Absorb) and...
Coronary revascularization with drug-eluting stents (DES) is very frequent, especially in acute coronary syndromes, but these metallic stents are permanent foreign bodies that activate the entire inflammatory system. Using bioresorbable stents (BRS) emerged as an alternative to this challenge. Although the initial results of the ABSORB study were not as expected (probably due to a...
Watch again Paradigm Shift: Magnesium in Bioresorbable Technology. Bioresorbable Scaffolds Innovation Highlights on our Youtube channel. Watch it now! Paradigm Shift: Magnesium in Bioresorbable Technology. Bioresorbable Scaffolds Innovation Highlights
Courtesy of the SBHCI. The 3-year outcomes of the ABSORB III trial, which randomized 2008 patients 2:1 to an everolimus eluting bioresorbable scaffold (1322 patients) vs. a metallic stent with permanent everolimus eluting polymer (686 patients), was published with low profile and great disappointment. Primary end-point, a composite of target vessel failure, occurred in 13.4% of patients receiving...
Courtesy of the SBHCI. The ABSORB II study sought to assess the mechanical properties of everolimus-eluting bioresorbable scaffolds, such as the increase in minimal lumen area and the recovery of the vasomotor properties of the treated artery. Last year saw the publishing of negative results for the primary endpoints, registering a higher rate of complications at...
By restoring vascular physiology and eliminating the inflammatory focus and the chance of fracture and neo atherosclerosis inherent to DES, bioresorbable scaffolds offer the potential to improve long term outcomes. A number of bioresorbable materials have been tested, mainly polylactic acid, with several limitations that have taken the Absorb bioresorbable scaffold out of the market....